Parabilis Medicines, Inc.
PBLS
Get informed when a big investor buys or sells
+ FollowMarket Cap$4.3B
Close$
$-15.32
141.5% downside
Current Fair Value
141.5% downsideOvervalued by 141.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $4.30 Billion |
|---|---|
| Enterprise Value | $3.27 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-92.4 |
| Beta | 0 |
| Outstanding Shares | 28,908,277 |
Return
| Return on Equity | -16.31% |
|---|---|
| Return on Assets | -14.54% |
| Return on Invested Capital | -15.44% |
Valuation & Multiples
| P/E Ratio | -1 |
|---|---|
| PEG | -1.97 |
| Price to Sales | - |
| Price to Book Ratio | 1.02 |
| Enterprise Value to Revenue | 22092.73 |
| Enterprise Value to EBIT | -19.04 |
| Enterprise Value to Net Income | -20 |
| Total Debt to Enterprise | 0.02 |
| Debt to Equity | 0.06 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 13, 2026
EPS Estimate
$-0.17
Average shareholder expectationRevenue Estimate
$16.67 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 342.35%▲ 342.35% |
|---|---|
| Total Invested | $2.71B |
| Investors Holding | 80▲ 80.00% |
ESG Score
No data
About Parabilis Medicines, Inc.
145 employees
CEO: Mathai Mammen Fog Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. It discovers and develops cell-penetrating miniproteins (CPMPs), which are specifically designed to target cancer-causing proteins inside cancer cells and neutralize t...